Mark Rabbat, MD
Cardiovascular Disease · Maywood, ILNPI 1114191327
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $239,477 of the $362,597 with a category attached, or 66.0%. Heartflow, Inc. accounts for 70.4% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $167,996, more than ten times the $3,905 reported in 2019. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $1444.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$255K
- E.r. Squibb & Sons, L.L.C.$94K
- Elucid Bioimaging Inc$8K
- Actelion Pharmaceuticals, Ltd$4K
- Bristol Myers Squibb$300
- GE HealthCare$112
- plus $280 from 6 others
Across 7 payments — averaging $20,468 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$143K
Across 1 payment — averaging $1250.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$1K
What the payments were for
- Consulting fees$81,38022%
- Speaking & faculty fees$239,47766%
- Travel & lodging$35,45110%
- Food & beverage$6,2892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 177 | $255,352 |
| E.r. Squibb & Sons, L.L.C. | 54 | $94,159 |
| Elucid Bioimaging Inc | 2 | $8,165 |
| Actelion Pharmaceuticals, Ltd | 6 | $4,230 |
| Bristol Myers Squibb | 1 | $300 |
| GE HealthCare | 1 | $112 |
| Medtronic | 1 | $93 |
| Boston Scientific | 2 | $56 |
| Amgen | 3 | $53 |
| Novartis | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$362,597 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $88,731 |
| JardianceEmpagliflozin | 58 | $59,281 |
| VascepaIcosapent Ethyl | 97 | $57,311 |
| Repatha SureclickEvolocumab | 37 | $43,487 |
| XareltoRivaroxaban | 27 | $39,936 |
| Icosapent Ethyl | 87 | $39,125 |
| EntrestoSacubitril/Valsartan | 12 | $18,438 |
| Atorvastatin Calcium | 317 | $3,100 |
| Metoprolol Succinate | 152 | $2,786 |
| Ezetimibe | 116 | $2,037 |
| Potassium Chloride | 12 | $1,344 |
| Rosuvastatin Calcium | 94 | $1,203 |
| Losartan Potassium | 72 | $1,048 |
| Amlodipine Besylate | 125 | $904 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 62 | $752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $19 | $39,93627 claims |
| NovartisEntresto | $35 | $18,43812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Maywood
- Niraj VarmaMaywood$522K
- Smit VasaiwalaMaywood$264K
- Clifford KavinskyMaywood$260K
- Gregory MacalusoMaywood$165K
- Dana JohnsonMaywood$104K
- Erin CoglianeseMaywood$36K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.